D.E. Shaw & Co
PVLA

D.E. Shaw & Co’s Palvella Therapeutics PVLA Stock Holding History

D.E. Shaw & Co’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,667
Closed -$504K – 6021
2021
Q4 		$504K Buy
+1,667
New +$534K ﹤0.01% 4401
2021
Q3 		– Sell
-968
Closed -$296K – 5287
2021
Q2 		$296K Buy
968
+729
+305% +$160K ﹤0.01% 4286
2021
Q1 		$49K Buy
+239
New +$52.2K ﹤0.01% 3967
2020
Q3 		– Sell
-191
Closed -$47K – 4236
2020
Q2 		$47K Sell
191
-40
-17% -$9.35K ﹤0.01% 3920
2020
Q1 		$42K Sell
231
-148
-39% -$37.3K ﹤0.01% 3840
2019
Q4 		$110K Sell
379
-718
-65% -$199K ﹤0.01% 3868
2019
Q3 		$299K Buy
1,097
+15
+1% +$5.81K ﹤0.01% 3465
2019
Q2 		$407K Buy
1,082
+165
+18% +$49.2K ﹤0.01% 3169
2019
Q1 		$246K Buy
917
+293
+47% +$69.6K ﹤0.01% 3309
2018
Q4 		$133K Buy
624
+323
+107% +$100K ﹤0.01% 3611
2018
Q3 		$135K Buy
+301
New +$131K ﹤0.01% 3597

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co's PVLA Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Palvella Therapeutics (PVLA) in Q1 2022, closing a stake of 1,667 shares — an estimated $504K sold.

D.E. Shaw & Co first reported a position in PVLA in Q3 2018 and held it in 11 quarters. The position peaked at $504K in Q4 2021. 71 funds tracked by Wall St. Rank hold PVLA as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Palvella Therapeutics position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,667 Palvella Therapeutics shares in Q1 2022, an estimated $504K.
  • D.E. Shaw & Co first reported a position in Palvella Therapeutics in Q3 2018 and held it in 11 quarters.
  • D.E. Shaw & Co's Palvella Therapeutics position peaked at $504K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.